Participate in scheduled live discussions and view transcripts of past live discussions.
Happening Now
Upcoming Live Discussions
Sorry, there are no upcoming live dicussions at this time!
Past Discussions
-
Myositis Skin Care and Treatment
Posted on: Wednesday, May 23, 2018 Time: 12:00 am Presenter Name: Dr. WerthDr. Werth has had many leadership roles in autoimmune skin disease, including as current president of the North American Rheumatologic Dermatology Society. She is co-founder of the Medical Dermatology Society, and a recipient of their lifetime achievement award.
She is recognized internationally for her expertise in dermatomyositis and served for seven years on the Medical Advisory Board of The Myositis Association.
Read Discussion -
Integrating Complementary Approaches in Treating Myositis
Posted on: Tuesday, November 14, 2017 Time: 12:00 pm Presenter Name: Lori A. Love, MD, PhDLori A. Love, MD, PhD worked for many years with the National Institutes of Health (NIH) and Food and the Drug Administration (FDA) at both the Center for Food Safety and Applied Nutrition and The Center for Drug Evaluation and Research. She has a special interest in both integrative health care and the idiopathic inflammatory myopathies. She also lives with myositis herself, so she has firsthand experience with the signs, symptoms, treatments, and frustrations of living with myositis. Please join us in welcoming Dr. Love to today's Live Discussion.
Read Discussion -
Follistatin Gene Therapy
Posted on: Monday, June 10, 2013 Time: 12:00 pm Presenter Name: Drs. Mendell and KasperDrs. Jerry Mendell and Brian Kaspar are investigators in the follistatin gene therapy trial for inclusion-body myositis patients now underway at Nationwide Children's Hospital.
Read Discussion -
Access to Treatment
Posted on: Tuesday, February 26, 2013 Time: 12:00 pm Presenter Name: Michelle GreerMichelle Greer answers questions about reimbursement and coverage issues with public and private insurers and the treatment you need for your disease. Michelle Greer is the vice president of sales for NuFACTOR and has been working with patients receiving IVIG for more than ten years.
Michelle Greer is the vice president of sales for NuFACTOR and has been working with patients receiving IVIG for more than ten years. She is also knowledgeable about issues with access to other myositis medications through public and private programs and insurers. Michelle provided counseling for individual myositis patients at the 2012 Annual Conference and serves as TMA’s resource for access to care issues. We welcome Michelle to TMA’s live discussion.
Read Discussion -
Acthar For Myositis
Posted on: Tuesday, February 12, 2013 Time: 12:00 pm Presenter Name: Dr. Todd LevineActhar, the only FDA-approved drug for myositis, has been available to treat myositis for years, but just recently has drawn attention because of Dr. Levine’s small study resulting in the improvement of several patients who had not responded to other drugs.
Dr. Levine, who is on TMA’s medical advisory board, is a member of Phoenix Neurological Associates. He is the founder and director of the Samaritan ALS clinic and co-director of the neurophysiology department at Banner Good Samaritan Medical Center.
Read Discussion -
Rituximab in Myositis
Posted on: Thursday, December 20, 2012 Time: 12:00 pm Presenter Name: Dr. OddisDr. Chester Oddis, a founding medical advisory board member of TMA, answers questions about the most ambitious study ever undertaken for a myositis drug. The RIM study focused on Rituximab in treating adults and children who have dermatomyositis or polymyositis. Dr. Oddis, who was the lead investigator for the multi-center study, is a professor of medicine in the department of Rheumatology and Clinical Immunology at the University of Pittsburgh and the director of the fellowship training program there. He has written extensively on the diagnosis and management of patients with myositis.
“There is some confusion about “Rituxan” and rituximab. Rituxan is a brand name for rituzimab, which is the generic name.”
Read Discussion